Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 1/20 | 0.54 |
| ▸ | MAOA | P21397 | 1/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.54 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.54 |
| ▸ | SCN4A | P35499 | 1/20 | 0.54 |
| ▸ | BLM | P54132 | 1/20 | 0.54 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.54 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.54 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.54 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.54 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.54 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.54 |
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 0.54 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | XBP1 | P17861 | 1/20 | 0.43 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.43 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.42 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3708084 | 0.87 | CYP2D6 (0.54) | CYP2D6MAOAMAPK1ADRA1ASCN4A | |
| SCHEMBL3701926 | 0.83 | SCN10A (0.57) | CYP2D6MAOAMAPK1ADRA1ASCN4A | |
| SCHEMBL6373767 | 0.81 | CYP2D6 (0.54) | CYP2D6MAOAMAPK1ADRA1ASCN4A | |
| SCHEMBL30413528 | 0.77 | CYP2D6 (0.50) | CYP2D6MAOAMAPK1ADRA1ASCN4A | |
| SCHEMBL10811842 | 0.76 | SCN9A (0.75) | CYP2D6MAOAMAPK1ADRA1ASCN4A | |
| SCHEMBL10984771 | 0.75 | CYP2D6 (0.59) | CYP2D6MAOAMAPK1ADRA1ASCN4A | |
| SCHEMBL9848578 | 0.75 | SCN9A (0.54) | CYP2D6MAOAMAPK1ADRA1ASCN4A | |
| SCHEMBL6373751 | 0.74 | MAPK1 (0.54) | CYP2D6MAOAMAPK1ADRA1ASCN4A | |
| SCHEMBL11067545 | 0.74 | CYP2D6 (0.50) | CYP2D6MAOAMAPK1ADRA1ASCN4A | |
| SCHEMBL17350619 | 0.74 | CYP2D6 (0.50) | CYP2D6MAOAMAPK1ADRA1ASCN4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9617228-B2 | Oligomer-containing substituted aromatic triazine compounds | NEKTAR THERAPEUTICS (US) | 2017-04-11 | — | — | US | disclosed |
| US-20160194294-A1 | OLIGOMER-CONTAINING SUBSTITUTED AROMATIC TRIAZINE COMPOUNDS | NEKTAR THERAPEUTICS | 2016-07-07 | — | — | US | disclosed |
| US-9266845-B2 | Oligomer-containing substituted aromatic triazine compounds | NEKTAR THERAPEUTICS (US) | 2016-02-23 | — | — | US | disclosed |
| US-20150065706-A1 | OLIGOMER-CONTAINING SUBSTITUTED AROMATIC TRIAZINE COMPOUNDS | NEKTAR THERAPEUTICS | 2015-03-05 | — | — | US | disclosed |
| US-8895553-B2 | Oligomer-containing substituted aromatic triazine compounds | NEKTAR THERAPEUTICS (US) | 2014-11-25 | — | — | US | disclosed |
| US-20140256732-A1 | OLIGOMER-CONTAINING SUBSTITUTED AROMATIC TRIAZINE COMPOUNDS | NEKTAR THERAPEUTICS (US) | 2014-09-11 | — | — | US | disclosed |
| US-8772479-B2 | Oligomer-containing substituted aromatic triazine compounds | NEKTAR THERAPEUTICS (US) | 2014-07-08 | — | — | US | disclosed |
| US-8772479-B2 | Oligomer-containing substituted aromatic triazine compounds | NEKTAR THERAPEUTICS (US) | 2014-07-08 | — | — | US | disclosed |
| US-20120122871-A1 | Oligomer-Containing Substituted Aromatic Triazine Compounds | NEKTAR THERAPEUTICS (US) | 2012-05-17 | — | — | US | disclosed |
| CN-102421763-A | Oligomer-containing substituted aromatic triazine compounds | NEKTAR THERAPEUTICS | 2012-04-18 | — | — | CN | disclosed |
| WO-2010132691-A1 | OLIGOMER-CONTAINING SUBSTITUTED AROMATIC TRIAZINE COMPOUNDS | NEKTAR THERAPEUTICS (US) | 2010-11-18 | — | — | WO | disclosed |
| US-4602017-A | Substituted aromatic compounds | SMITHKLINE BEECHAM CORPORATION(A PENNSYLVANIA CORPORATION) | 1986-07-22 | — | — | US | disclosed |
| US-4486354-A | ANTICONVULSANTS | BURROUGH WELLCOME CO. | 1984-12-04 | — | — | US | disclosed |
| EP-0021121-A1 | 1,2,4-Triazine derivatives, process for preparing such compounds and pharmaceutical compositions containing them | THE WELLCOME FOUNDATION LIMITED (GB) | 1981-01-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120122871-A1 | Oligomer-Containing Substituted Aromatic Triazine Compounds | NOD2, HTT, CUL5 | CYP2D6 1003/4885MAOA 440/4885MAPK1 4483/4885 |
| US-20140256732-A1 | OLIGOMER-CONTAINING SUBSTITUTED AROMATIC TRIAZINE COMPOUNDS | NOD2, HTT, IPO5 | CYP2D6 1051/4885MAOA 361/4885MAPK1 4739/4885 |
| US-20160194294-A1 | OLIGOMER-CONTAINING SUBSTITUTED AROMATIC TRIAZINE COMPOUNDS | NOD2, HTT, IPO5 | CYP2D6 1051/4885MAOA 361/4885MAPK1 4739/4885 |
| US-20150065706-A1 | OLIGOMER-CONTAINING SUBSTITUTED AROMATIC TRIAZINE COMPOUNDS | NOD2, HTT, IPO5 | CYP2D6 1051/4885MAOA 361/4885MAPK1 4739/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.